Memorial Sloan Kettering Cancer Center ✓

@MSKCancerCenter · New York, New York · joined 28 Mar 2009

Where you’re treated first, matters. To make an appointment: 877-871-9362

103 957Followers

1 927Following

27 185Posts total

61.9KViews on collected posts

Postingan terbaru

Memorial Sloan Kettering Cancer Center ✓@MSKCancerCenter3 Sep

Some call it chic. We call it our mission. https://t.co/z3eoUwqtPp 558 views · 1 likes · 0 reposts · 0 replies Open on X →

Memorial Sloan Kettering Cancer Center ✓@MSKCancerCenter3 Sep

🚨 New research published in @NEJM shows daraxonrasib is showing early but strong signs it could be effective against lung cancer. In a phase 1/2 clinical trial led by MSK thoracic medical oncologist @KCArbourMD, more than 30% of patients with previously treated metastatic https: 1K views · 14 likes · 0 reposts · 2 replies Open on X →

Memorial Sloan Kettering Cancer Center ✓@MSKCancerCenter31 Aug

What if a blood test could detect lymphoma more precisely than an imaging scan? MSK lymphoma specialist Dr. Mark Roschewski is studying how blood-based tests for circulating tumor DNA may help guide treatment decisions and determine whether cancer remains after therapy. Learn ht 3.5K views · 20 likes · 6 reposts · 3 replies Open on X →

Memorial Sloan Kettering Cancer Center ✓@MSKCancerCenter26 Aug

The @FDA has approved #daraxonrasib for certain patients with metastatic pancreatic cancer. MSK’s @EileenMOReilly led the phase 3 trial at MSK showing it doubled median survival compared with chemotherapy. “To date in my career, I have not seen this level of benefit from any htt 25.2K views · 217 likes · 58 reposts · 5 replies Open on X →

Memorial Sloan Kettering Cancer Center ✓@MSKCancerCenter22 Aug

@MSKCancerCenter @TheLancet Solid PFS data but <1% Black participants out of 747 is hard to overlook. Can't set a new standard of care on evidence this narrow. 63 views · 0 likes · 0 reposts · 0 replies Open on X →

Memorial Sloan Kettering Cancer Center ✓@MSKCancerCenter21 Aug

New clinical trial data led by MSK’s Dr. Robert Motzer supports a novel combination therapy for patients with advanced clear cell renal cell carcinoma whose disease progressed after immunotherapy. The findings, published in @TheLancet, point to a potential new treatment option. 4.8K views · 29 likes · 9 reposts · 3 replies Open on X →

Memorial Sloan Kettering Cancer Center ✓@MSKCancerCenter19 Jun 2025

@MSKCancerCenter Dr. Drebin's dual clinical and executive roles should benefit both patients and staff. 183 views · 1 likes · 0 reposts · 0 replies Open on X →

Memorial Sloan Kettering Cancer Center ✓@MSKCancerCenter19 Jun 2025

@MSKCancerCenter Much deserved and earned. Congrats. 180 views · 0 likes · 0 reposts · 0 replies Open on X →

Memorial Sloan Kettering Cancer Center ✓@MSKCancerCenter18 Jun 2025

Dr. Jeffrey Drebin, Chair of the Department of Surgery, has been named MSK's next Chief Physician Executive. He will succeed esteemed neuro-oncologist Dr. Lisa DeAngelis who will retire this summer. In this role, Dr. Drebin will lead all clinical services and research, medical

26.4K views · 126 likes · 16 reposts · 5 replies Open on X →

Dibandingkan akun berukuran sama

6 postingan dari 90 hari terakhir, dibandingkan dengan rentang 100K–1M pengikut. tampil ke lebih banyak orang dibanding akun seukurannya.

Median tayangan2 254akun ini5 983median untuk 100K–1M

Jangkauan, %2.17%akun ini1.49%median untuk 100K–1M

Interaksi, %0.86%akun ini0.93%median untuk 100K–1M

Metrik	Akun ini	Median untuk 100K–1M	Rasio
Median tayangan per postingan	2 254	5 983	0.38×
Jangkauan (tayangan ÷ pengikut)	2.17%	1.49%	1.46×
Tingkat interaksi	0.86%	0.93%	0.93×

Akun lain pada rentang ini → Bandingkan dengan akun lain → Bagaimana tolok ukur ini disusun →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

26.4K18 Jun

18019 Jun

183

4.8K21 Aug

6322 Aug

25.2K26 Aug

3.5K31 Aug

1K3 Sep

558

Last 9 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.58%18 Jun

0.00%19 Jun

0.55%

0.86%21 Aug

0.00%22 Aug

1.14%26 Aug

0.86%31 Aug

1.76%3 Sep

0.18%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 100K–1M accounts is 0.93%.

What the audience does

Likes73.0%408 in total

Reposts15.9%89 in total

Replies3.2%18 in total

Quotes2.9%16 in total

Bookmarks5.0%28 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.